-
Alzheimer Dementia: The phosphorylation characteristics of Tau protein are different in different brain diseases
Time of Update: 2021-12-26
They used the total number of years participating in contact sports as a proxy for cumulative RHI exposure, and further tested the hypothesis that the total number of years can predict increased phosphorylation of CTE-related tau epitopes .
-
Lancet Neurol: Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers for Alzheimer's disease and frontotemporal degeneration
Time of Update: 2021-11-01
Plasma tau protein phosphorylation at threonine 217 (p-tau217) and plasma tau protein phosphorylation at threonine 181 (p-tau181) are related to the tau pathology of Alzheimer's disease . Recently,
-
Early accumulation of tau in the brain heralds memory decline in Alzheimer's disease patients
Time of Update: 2021-11-01
"There are different biomarkers in the rapid development of Alzheimer's disease in recent years, allowing us to measure and detect the early signs of the disease in patients," said Marco Bucci, the first author of the study, of the Alzheimer's Research Center.
-
New mechanism of Mol Cell︱ Alzheimer's disease: Tau protein oligomerization induces nuclear cell
Time of Update: 2021-10-21
On August 27, 2021, in the latest paper published online in Molecular Cell with the title "Interaction of Tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of Tauopathy", Lulu Jiang of Boston University, USA ( Article 1), Benjamin Wolozin (corresponding author) and others have studied these scientific issues .
-
Alzheimer Dementia: Alzheimer's disease, apolipoprotein B is a new marker of early tau pathology
Time of Update: 2021-10-09
The important significance of this study lies in the discovery: CSF apoB is significantly related to the early tau imbalance in asymptomatic subjects, and it has identified the high-risk population that is likely to develop visual and spatial cognitive decline over time .
-
Nature Sub-Journal: Plasma phosphorylated tau combined with other methods can predict Alzheimer's disease
Time of Update: 2021-09-06
On May 24, 2021, Oskar Hansson, Sebastian Palmqvist and other researchers from Lund University in Sweden jointly published an online publication entitled "Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures" in the journal Nature Medicine.
-
Alzheimer's & Dementia: Head injury is related to tau deposition in the brains of MCI and AD patients
Time of Update: 2021-09-04
Biological changes, such as more tau, are related to the history of HI in people with cognitive impairment.
Alzheimer's & Dementia Head injury is associated with tau deposition on PET in MCI and AD patients.
-
Alzheimers Dementia: Different tau proteins have inconsistent predictive effects on cognitive ability
Time of Update: 2021-08-27
However, it is currently looking for other tau fragments or phosphorylation sites to improve the specificity of the diagnosis and prognosis of AD dementia .
-
Anesthesia may affect the spread of tau protein in the brain and promote Alzheimer's disease
Time of Update: 2021-08-12
In order to see whether tau protein stimulates microglia to promote the development of Alzheimer's disease pathology, MGH researchers and their colleagues conducted experiments with an inhaled anesthetic called sevoflurane .
-
to remove hyperphosphorylated tau, which can potentially treat diseases such as Alzheimer's
Time of Update: 2021-08-08
The study designed and synthesized a new type of dephosphorylation targeting chimera (DEPTAC) to specifically promote the binding of tau to protein phosphatase 2A (PP2A-Bα) containing the Bα subunit, which is the most active tau phosphate in the brain Enzyme .
-
Alzheimer Dementia: Fudan University Yu Jintai's new discovery: the complex relationship between
Time of Update: 2021-08-01
Tau lesions may play an important role in the relationship between blood pressure and cognition, and have obvious age and BP type dependence.
Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study.
-
The clinical results of Phase 2 of the innovative tau protein vaccine for the treatment of Alzheimer's disease are published
Time of Update: 2021-06-30
This article is reproduced from the WeChat public account Axon Neuroscience of "DrugMaker" today announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-Journal Nature Aging .
-
Phase 2 clinical results of innovative tau protein vaccine for the treatment of Alzheimer's disease published
Time of Update: 2021-06-22
Today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-published Nature Aging .
-
Courier treatment of Alzheimer's disease, Phase 2 clinical results of innovative tau protein vaccine published
Time of Update: 2021-06-22
▎The content team editor of WuXi AppTec today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-published Nature Aging .
-
Phase 2 clinical results of innovative tau protein vaccine for the treatment of Alzheimer's disease published
Time of Update: 2021-06-21
In the subgroup of AD patients confirmed by AD biomarkers amyloid deposition and tau protein aggregation, AADvac1, compared with placebo, delayed the clinical decline detected by CDR-SB by 27% (p=0.